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Identity 
Other names: HNF3A, MGC33105, TCF3A 




The transcribed region of FOXA1 extends only to 5400 
bases and contains two exons and one intron. This gene 
is amplified in breast, esophageal, lung, and thyroid 
carcinomas. No deletions or chromosomal 
translocations have been reported. MIPOL1 and 
C14orf25 are the two adjoining genes. MIPOL1 has 
been described as a tumor suppressor gene in 
nasopharyngeal carcinoma, whereas the function of 
C14orf25 is unknown. 
Transcription 
FOXA1 is expressed predominantly in liver and is 
highly responsive to hormonal manipulation. Insulin 
suppresses its expression in embryonic stem cells as 
well as in breast cancer cells, whereas retinoic acid, 
estrogen, androgen, and heregulin induce its 
expression. The developmental transcription factors 
Oct-4 and SOX4 repress FOXA1 expression, whereas 
SOX17 and GATA-3 increase its expression. No splice 
variants have been reported. 542 base long 
promoter/enhancer is sufficient for liver-specific 
expression. This region binds to transcription factors 
TTF1 and NF-1. By binding to its own 
enhancer/promoter, FOXA1 autoregulates its 
expression. Peroxisome Proliferator Activated Receptor 
gamma also upregulates FOXA1 expression, although 
region of the promoter/enhancer involved in this 
upregulation is yet to be characterized. 
 
FOXA1 is located on chromosome 14q21.1 and the transcribed region including an intron spans only 5300 bases. This protein binds to 
chromatinized DNA and, therefore, described as a "pioneer factor". 
 













FOXA1 is a 473 amino acid long transcription factor 
that binds to the consensus sequence 
A(A/T)TRTT(G/T)RYTY using the central region of 
the protein. Crystallography showed DNA binding 
domain in a winged helix-loop-helix configuration. 
Both N-terminus and C-terminus have transactivation 
domains. In silico analysis revealed 11 putative 
acetylation sites; acetylation sites in the DNA binding 
domain inhibit interaction with chromatin. The N-
terminus has a putative caseine kinase 1 
phosphorylation site. 
Expression 
FOXA1 was originally identified as a transcription 
factor that regulates gene expression in endoderm-
derived tissues such as liver and lungs. Subsequent 
studies showed expression in pancreas, breast, prostate, 
bladder, intestine, and seminal vesicle. During 
embryogenesis, expression is seen in tissues derived 
from both foregut and hindgut endoderm (liver, lung, 
pancreas, stomach, intestine, prostate, and bladder). 
Organs derived from ectoderm (forebrain, floor plate, 
olfactory epithelium) and mesoderm (kidney, vagina, 
uterus, seminal and coagulating glands) also show 
expression. FOXA1 along with FOXA2 is required for 
normal bile duct development as deletion of FOXA1/2 
in embryonic liver leads to hyperplasia of the billiary 
tree. Absence of FOXA1 in mammary gland leads to 
impaired ductal morphogenesis and reduction in the 
number of estrogen receptor-positive luminal epithelial 
cells. 
Localisation 
FOXA1 is localized predominantly in the nucleus. 
transforming growth factor beta 1 treatment results in 
cytoplasmic localization of the protein, which may be 
dependent on protein kinase C. 
Function 
FOXA1 binds to chromatinized DNA and opens the 
chromatin to allow binding of additional transcription 
factors. Specific histone modification such as histone 
H3 lysine 4 methylation guides recruitment of other 
factors. FOXA1 facilitates the recruitment of nuclear 
receptors including estrogen receptor, androgen 
receptor and glucocorticoid receptor. FOXA1 binding 
leads to both activation or repression of genes. These 
gene-specific effects involve interaction with or 
recruitment of other transcription factors such as SRC-
3, USF2, TLE3, COUP-TFII, SHP, SMAD3, and 
HDAC7. 
Homology 
FOXA1 belongs to the 40-member FOX family of 
transcription factors. FOXA1, FOXA2, and FOXA3 
form a subfamily and share a 110 amino acid long 




Coding region variation Ala83Thr, which is within the 
N-terminal transactivation domain, has been observed. 
However, this variation is not linked to breast cancer or 
maturity onset diabetes. 










Breast cancers that express estrogen receptor and 
progestrone receptor (ER+/PR+) demonstrate elevated 
FOXA1 expression. Amplification of the genomic 
region encompassing FOXA1 is also observed in 
ER+/PR+ breast cancer. A small subgroup of ER-/PR- 
negative breast cancers express FOXA1 and ER-
/FOXA1- tumors show 3.6 fold enhanced recurrence 
rate compared to ER-/FOXA1+ tumors. 
Prognosis 
FOXA1-positivity ER+/PR+ breast cancer is associated 
with favorable prognosis. 
Prostate cancer 
Disease 
FOXA1 is expressed in prostate cancer regardless of 
Gleason grade score and the expression is higher in 
metastatic disease. In transgenic animal models of 




FOXA1 is expressed in normal and well-differentiated 
cancer but the expression is lost in undifferentiated 
cancer cells. Loss of FOXA1 expression correlates with 
epithelial-to-mesenchymal transition. 
Esophageal squamous cell carcinoma 
Disease 
Cancers that have metastasized to lymphnodes express 
higher levels of FOXA1 along with its target gene 
KRT7. 
Anaplastic thyroid carcinoma 
Disease 
Overexpressed in aggressive thyroid cancers and is 
amplified in these cancers. FOXA1 increases 
proliferation of these cells. 
Diabetes 
Disease 
FOXA1 deficient mice are growth retarded and 
hypoglycemic due to defects in insulin secretion. 
However, the corresponding effects in human have not 
been reported. 
Diet restriction-induced longevity 
Note 
PHA-4, the FOXA1, A2 and A3 ortholog in C. elegans 
is essential for diet-restriction-induced longevity. 
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